β-galactoside α2, 6-sialyltransferse gene (ST6GAL) family has two members, which encode corresponding enzymes ST6Gal I and ST6Gal II. The present atudy was to investigate whether and how ST6GAL family involved in multidrug resistance (MDR) in human leukemia cell lines and bone marrow mononuclear cells (BMMC) of leukemia patients. Real-time PCR showed a high expression level of ST6GAL1 gene in both MDR cells and BMMCs (*P<0.05). Alternation of ST6GAL1 levels had a significant impact on drug-resistant phenotype changing of K562 and K562/ADR cells both in vitro and in vivo. However, no significant changes were observed of ST6GAL2 gene. Further data revealed that manipulation of ST6GAL1 modulated the activity of phosphoinositide 3 kinase (PI3K)/Akt signaling and consequently regulated the expression of P-glycoprotein (P-gp, *P<0.05) and multidrug resistance related protein 1 (MRP1, *P<0.05), which are both known to be associated with MDR. Therefore we postulate that ST6GAL1 is responsible for the development of MDR in human leukemia cells probably through medicating the activity of PI3K/Akt signaling and the expression of P-gp and MRP1.
References
[1]
Wang H, Wang X, Li Y, Liao A, Fu B, et al. (2012) The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Pharmazie 67: 187–192.
[2]
Leslie EM, Deeley RG, Cole SPC (2005) Multidrug resistance proteins: role of P-glycoprotein MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216–237.
[3]
Bosch TM (2008) Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods in Molecular Biology 448: 63–76.
[4]
Gergely S, Paterson JK, Ludwig JA, Genthem CB, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234.
[5]
Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, et al. (2007) Expression of multidrug resistance 1 (mdr1), multidrug resistance-related protein 1 (mrp1), lung resistance protein (lrp), and breast cancer resistance protein (bcrp) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 86: 166–173.
[6]
Nakano M, Saldanha R, G？bel A, Kavallaris M, Packer NH (2011) Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol Cell Proteomics 10: M111.009001.
[7]
Zhang Z, Zhao Y, Jiang L, Miao X, Zhou H, et al. (2012) Glycomic alterations are associated with multidrug resistance in human leukemia. Int J Biochem Cell Biol 44: 1244–1253.
[8]
Varki NM, Varki A (2007) Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 87: 851–857.
[9]
Hedlund M, Ng E, Varki A, Varki NM (2008) α2, 6–linked sialic acids on N-Glycans modulate carcinoma differentiation in vivo. Cancer Res 68: 388–394.
[10]
Milflores-Flores L, Millán-Pérez L, Santos-López G, Reyes-Leyva J, Vallejo-Ruiz V (2012) Characterization of P1 promoter activity of the beta-galactoside alpha2,6-sialyltransferase I gene (siat 1) in cervical and hepatic cancer cell lines. J Biosci 37: 259–67.
[11]
Swindall AF, Bellis SL (2011) Sialylation of the fas death receptor by ST6Gal-I provides protection against fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 286: 22982–22990.
[12]
Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, et al. (2013) ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res 73: 2368–2378.
[13]
Gretschel S, Haensch W, Schlag PM, Kemmner W (2003) Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer. Oncology 65: 139–145.
[14]
Schultz M, Swindall A, Wright J, Sztul E, Landen C, et al. (2013) ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res 6: 25 doi: 10.1186/1757-2215-6-25.
[15]
Zhang Z, Sun J, Hao L, Liu C, Ma H, et al. (2013) Modification of glycosylation mediates the invasive properties of murine hepatocarcinoma cell lines to lymph nodes. Plos one 8: e65218.
[16]
Dalziel M, Huang RY, Dall'Olio F, Morris JR, TaylorPapadimitriou J, et al. (2001) Mouse ST6Gal sialyltransferase gene expression during mammary gland lactation. Glycobiology 11: 407–412.
[17]
Petit D, Mir AM, Petit JM, Thisse C, Delannoy P, et al. (2010) Molecular phylogeny and functional genomics of β-Galactoside α2, 6-Sialyltransferases that explain ubiquitous expression of ST6GAL1 gene in amniotes. J Biol Chem 285: 38399–38414.
[18]
Takashima S, Tsuji S, Tsujimoto M (2003) Comparison of the enzymatic properties of mouse beta-galactoside alpha2, 6-sialyltransferases, ST6GalI and II. J Biochem (Tokyo) 134: 287–296.
[19]
Takashima S, Tsuji S, Tsujimoto M (2002) Characterization of the second type of human β-galactoside α 2,6-sialyltransferase(ST6Gal II), which sialylates Gal β 1,4GlcNAc structures on oligosaccharides preferentially. Genomic analysis of human sialyltransferase genes. J Biol Chem 277: 45719–45728.
[20]
Bellacosa A, Kumar CC, Di CA, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29–86.
[21]
Garcia MG, Alaniz LD, Russo RIC, Alvarez E, Hajos SE (2009) PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leukemia Research 33: 288–296.
[22]
Cordo RRI, García MG, Alaniz L, Blanco G, Alvarez E, et al. (2008) Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 122: 1012–1018.
[23]
Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, et al. (2012) Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-pecursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59: 83–89.
[24]
Wu Q, Chen Y, Cui G, Cheng Y (2009) LY294002 inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro. Journal of Huazhong Univercity of Science and Technology 29: 451–456.
[25]
Barancik M, Bohacova V, Sedlak J, Sulova Z, Breier A (2006) LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. European journal of pharmaceutical sciences 29: 426–434.
[26]
Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, et al. (2007) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427–438.
[27]
Conde I, Pabón D, Jayo A, Lastres P, González-Manchón C (2010) Involvement of ERK1/2, p38 and PI3K in megakaryocytic differentiation of K562 cells. European Journal of Haematology 84: 430–440.
[28]
Kars MD, Iseri OD, Ural AU, Gunduz U (2007) In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Reasearch 27: 4031–4038.
[29]
Daiane SM, Juliana ZS, Robert TB, Luis FM, Gilma ST (2010) Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leukemia Research 34: 757–762.
[30]
Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, et al. (2013) α2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int J Biochem Cell Biol pii: S1357-2725(13)00152-0.
[31]
Li J, Wang Y, Xie Y, Xu Z, Yang J, et al. (2012) Altered mRNA expressions of sialyltransferases in human gastric cancer tissues. Med Oncol 29: 84–90.
[32]
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005–1009.
[33]
Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, et al. (2009) ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 9: 357.
[34]
Inagaki Y, Tang W, Guo Q, Kokudo N, Sugawara Y, et al. (2007) Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues. Hepatogastroenterology 54: 53–57.
[35]
Schultz MJ, Swindall AF, Bellis SL (2012) Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev 31: 501–518.
[36]
Dalziel M, Dall'Olio F, Mungul A, Piller V, Piller F (2004) Ras oncogene induces β -galactoside α 2, 6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. Eur J Biochem 271: 3623–3634.
[37]
Baran Y, Bielawski J, Gunduz U, Ogretmen B (2011) Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol 137: 1535–1544.
[38]
Pandurangan AK (2013) Potential Targets for Prevention of Colorectal Cancer: a Focus on PI3K/Akt/mTOR and Wnt Pathways. Asian Pac J Cancer Prev 14: 2201–2205.
[39]
Dobbin ZC, Landen CN (2013) The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 14: 8213–8227.
[40]
Abdul-Ghani R, Serra V, Gyorffy B, Jurchott K, Solf A, et al. (2006) The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743–1752.
[41]
Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102: 972–980.
[42]
Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, et al. (2004) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18: 267–275.
[43]
Grandage VL, Gale RE, Linch DC, Khwaja A (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19: 586–594.
[44]
Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, et al. (2006) Activation of FGFR1b signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 20: 979–986.
[45]
Matkovic K, Brugnoli F, Bertagnolo V, Banfic H, Visnjic D (2006) The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia 20: 941–951.
[46]
Maraldi T, Bertacchini J, Benincasa M, Guida M, De Pol A, et al. (2011) Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. Int J Oncol 38: 427–435.
[47]
Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, et al. (2007) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427–438.
